Extended Follow-Up Analysis of First-Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: A Real-World Multicenter Prospective Cohort Study.

However, since most patients who received thoracic RT achieved a complete or partial best response (90.5%), while the subgroup analysis of patients who responded to systemic therapy showed a borderline significant survival benefit ( p = 0.050), the beneficial effect of thoracic RT administered during first‐line treatment can reasonably be regarded as that of consolidative RT in a real‐world clinical setting [ 2 , 19 , 20 ].

also in 6,883 other papers